Sensory loss adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 7,941 adverse event reports that record the MedDRA preferred term Sensory loss. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 417 reports in the 12 months to June 2026 and 377 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,082 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 417 (under 0.1%) record this term. Reports for patients aged 18 to 44 were 22.1% of the reports that record this term and 12.3% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 138 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Sensory loss name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetaminophen		187
Acetylsalicylic Acid		71
Adalimumab	Tumor necrosis factor blocker	36
Alemtuzumab	CD52-directed cytolytic antibody	26
Aliskiren	Renin inhibitor	154
Aliskiren hemifumarate	Renin inhibitor	168
Altace		160
Amitriptyline		61
Amlodipine	Calcium channel blocker	175
Amlodipine Besilate		31
Amlodipine besylate	Dihydropyridine calcium channel blocker	152
Ampyra	Potassium channel blocker	75
Aspirin	Nonsteroidal anti-inflammatory drug	197
Atacand	Angiotensin 2 receptor blocker	128
Atorvastatin		60
Atorvastatin calcium	HMG-CoA reductase inhibitor	37
Aubagio	Pyrimidine synthesis inhibitor	79
Avonex	Interferon beta	89
Baclofen	gamma-Aminobutyric acid-ergic agonist	26
Bisoprolol	beta-Adrenergic blocker	184
Bisoprolol fumarate	beta-Adrenergic blocker	41
Bupivacaine	Amide local anesthetic	41
Calcium carbonate	Blood coagulation factor	158
Candesartan	Angiotensin 2 receptor blocker	111
Candesartan cilexetil	Angiotensin 2 receptor blocker	85
Capecitabine	Nucleoside metabolic inhibitor	34
Carboplatin	Platinum-based drug	38
Ciprofloxacin	Fluoroquinolone antibacterial	57
Clonazepam	Benzodiazepine	83
Codeine		50
Codeine phosphate		26
Copaxone		80
Cosentyx	Interleukin-17A antagonist	257
Crestor	HMG-CoA reductase inhibitor	29
Cyclophosphamide	Alkylating drug	61
Cymbalta		34
Cytarabine	Nucleoside metabolic inhibitor	34
Dexamethasone	Corticosteroid	29
Diazepam	Benzodiazepine	71
Diphenhydramine	Histamine-1 receptor antagonist	63
Diphenhydramine hydrochloride	Histamine-1 receptor antagonist	133
Domperidone		64
Dupixent	Interleukin-4 receptor alpha antagonist	34
Enbrel	Tumor necrosis factor blocker	169
Entresto	Angiotensin 2 receptor blocker	25
Ergocalciferol	Provitamin D2 compound	193
Esomeprazole	Proton pump inhibitor	126
Esomeprazole magnesium	Proton pump inhibitor	122
Esomeprazole Magnesium Naproxen		77
Esomeprazole magnesium trihydrate		30
Esomeprazole sodium	Proton pump inhibitor	28
Fentanyl	Opioid agonist	31
Finasteride	5-alpha reductase inhibitor	29
Fluorouracil	Nucleoside metabolic inhibitor	25
Forteo	Parathyroid hormone analog	28
Fosamax	Bisphosphonate	25
Gabapentin	Anti-epileptic agent	82
Gilenya	Sphingosine 1-phosphate receptor modulator	309
Gliclazide		178
Gravol	Histamine-1 receptor antagonist	173
Herceptin	HER2/neu receptor antagonist	25
Humalog	Insulin analog	36
Humira		181
Ibuprofen	Nonsteroidal anti-inflammatory drug	30
Infliximab	Tumor necrosis factor blocker	25
Irbesartan	Angiotensin 2 receptor blocker	281
Januvia	Dipeptidyl peptidase 4 inhibitor	251
Kesimpta	CD20-directed cytolytic antibody	64
Kisqali	Kinase inhibitor	25
Levetiracetam		33
Levothyroxine		43
Levothyroxine sodium	l-Thyroxine	135
Lidocaine	Amide local anesthetic	30
Lipitor	HMG-CoA reductase inhibitor	286
Lisinopril	Angiotensin converting enzyme inhibitor	163
Lorazepam	Benzodiazepine	67
Lyrica		188
Metformin	Biguanide	225
Metformin hydrochloride	Biguanide	115
Methotrexate	Folate analog metabolic inhibitor	272
Methotrexate sodium	Folate analog metabolic inhibitor	35
Methylprednisolone	Corticosteroid	64
Methylprednisolone sodium succinate	Corticosteroid	162
Mirtazapine		87
Morphine	Opioid agonist	140
Morphine sulfate	Opioid agonist	131
Mycophenolate mofetil	Antimetabolite immunosuppressant	35
Naproxen	Nonsteroidal anti-inflammatory drug	40
Neurontin		37
Nexium	Proton pump inhibitor	64
Nexium 24HR	Proton pump inhibitor	36
Ocrevus	CD20-directed cytolytic antibody	118
Omeprazole	Proton pump inhibitor	129
Ondansetron	Serotonin-3 receptor antagonist	133
Ondansetron hydrochloride	Serotonin-3 receptor antagonist	57
Oxycodone hydrochloride	Opioid agonist	42
OxyContin	Opioid agonist	43
Paclitaxel	Microtubule inhibitor	41
Paroxetine	Serotonin reuptake inhibitor	59
Paroxetine hydrochloride	Serotonin reuptake inhibitor	53
Phosphorus		48
Prednisolone	Corticosteroid	69
Prednisolone sodium phosphate	Corticosteroid	26
Prednisone	Corticosteroid	243
Pregabalin		52
Prochlorperazine	Phenothiazine	171
Procyclidine		41
Propecia	5-alpha reductase inhibitor	41
Quetiapine	Atypical antipsychotic	57
Ramipril	Angiotensin converting enzyme inhibitor	104
Rasilez		71
Rebif	Interferon beta	91
Remicade	Tumor necrosis factor blocker	86
Revlimid	Thalidomide analog	50
Rituxan	CD20-directed cytolytic antibody	42
Rituximab	CD20-directed cytolytic antibody	239
Sandostatin LAR Depot		27
Sertraline	Serotonin reuptake inhibitor	32
Simvastatin	HMG-CoA reductase inhibitor	32
Sitagliptin phosphate	Dipeptidyl peptidase 4 inhibitor	32
Stelara	Interleukin-12 antagonist	40
Synthroid	l-Thyroxine	138
Tacrolimus	Calcineurin inhibitor immunosuppressant	32
Tamoxifen		26
Tasigna	Kinase inhibitor	28
Tecfidera		69
Teriflunomide	Pyrimidine synthesis inhibitor	38
Tramadol		65
Tramadol hydrochloride	Opioid agonist	44
Tums Ultra		28
Tysabri	Integrin receptor antagonist	104
Venlafaxine	Serotonin and norepinephrine reuptake inhibitor	33
Xeljanz	Janus kinase inhibitor	37
Xolair	Anti-IgE	29
Zestril	Angiotensin converting enzyme inhibitor	75
Zofran		48
Zolpidem	gamma-Aminobutyric acid A receptor positive modulator	102
Zometa		49

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 50 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Sensory loss name, in order of name
Class	Reports with this term
5-alpha reductase inhibitor	80
Alkylating drug	79
Amide local anesthetic	98
Angiotensin 2 receptor blocker	647
Angiotensin converting enzyme inhibitor	344
Anti-epileptic agent	115
Antimetabolite immunosuppressant	55
Aromatase inhibitor	55
Atypical antipsychotic	178
Benzodiazepine	263
beta-Adrenergic blocker	246
Biguanide	350
Blood coagulation factor	167
Calcineurin inhibitor immunosuppressant	56
Calcium channel blocker	197
CD20-directed cytolytic antibody	483
Corticosteroid	656
Dihydropyridine calcium channel blocker	156
Dipeptidyl peptidase 4 inhibitor	289
Fluoroquinolone antibacterial	79
Folate analog metabolic inhibitor	307
gamma-Aminobutyric acid A receptor positive modulator	109
GLP-1 receptor agonist	57
HER2/neu receptor antagonist	55
Histamine-1 receptor antagonist	412
HMG-CoA reductase inhibitor	407
Insulin analog	93
Integrin receptor antagonist	140
Interferon beta	193
Interleukin-17A antagonist	259
Janus kinase inhibitor	52
Kinase inhibitor	172
l-Thyroxine	273
Microtubule inhibitor	58
Nonsteroidal anti-inflammatory drug	312
Nucleoside metabolic inhibitor	149
Opioid agonist	544
Phenothiazine	180
Platinum-based drug	74
Potassium channel blocker	82
Proton pump inhibitor	558
Provitamin D2 compound	193
Pyrimidine synthesis inhibitor	117
Renin inhibitor	156
Serotonin and norepinephrine reuptake inhibitor	61
Serotonin reuptake inhibitor	250
Serotonin-3 receptor antagonist	190
Sphingosine 1-phosphate receptor modulator	336
Thalidomide analog	72
Tumor necrosis factor blocker	369

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Sensory loss, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Sensory loss
Age	Reports	Share
Under 2	4	0.1%
2 to 11	35	0.4%
12 to 17	129	1.6%
18 to 44	1,756	22.1%
45 to 64	2,186	27.5%
65 to 74	958	12.1%
75 and over	478	6%
Age not given	2,395	30.2%

Sex of the patient in the reports that record Sensory loss
Sex	Reports	Share
Female	4,670	58.8%
Male	2,767	34.8%
Unknown or not given	504	6.3%

Age and sex are as the report gives them. 46.8% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Sensory loss: adverse event reports that record this term. https://reportedreactions.com/reaction/sensory-loss/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Sensory loss mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page